{
    "eid": "2-s2.0-85130972397",
    "title": "The impact of warfarin on overall survival in cancer patients",
    "cover-date": "2022-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Cancer-associated thrombosis",
        "Low-molecular weight heparin",
        "Oral anticoagulants",
        "Warfarin"
    ],
    "authors": [
        "Thita Chiasakul",
        "Jeffrey I. Zwicker"
    ],
    "citedby-count": 2,
    "ref-count": 61,
    "ref-list": [
        "Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer",
        "Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism",
        "I. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer, low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer",
        "Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial",
        "Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer",
        "Edoxaban for the treatment of cancer-associated venous thromboembolism",
        "Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)",
        "Apixaban for the treatment of venous thromboembolism associated with cancer",
        "Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States",
        "Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs",
        "American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer",
        "Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update",
        "NCCN Guideline on Cancer-associated Venousthromboembolic Disease. Version 2. 2021",
        "Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer",
        "Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75",
        "Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study",
        "Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period",
        "Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism",
        "Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials",
        "Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial",
        "Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial",
        "Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer",
        "Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75",
        "A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B",
        "The first international urokinase/warfarin trial in colorectal cancer",
        "Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer",
        "Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study",
        "Oral anticoagulation for prolonging survival in patients with cancer",
        "Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis",
        "Risk of prostate cancer death in long-term users of warfarin: a population-based case-control study",
        "The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink",
        "Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer",
        "Impact of concurrent medication use on pancreatic cancer survival-SEER-medicare analysis",
        "Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer",
        "Anticoagulants and breast cancer survival: a Nationwide cohort study",
        "Overall survival with warfarin vs. Low-molecular-weight heparin in cancer-associated thrombosis",
        "Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism.Duration of Anticoagulation Trial",
        "More on: vitamin K antagonists and cancer",
        "Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study",
        "Long-term use of vitamin K antagonists and incidence of cancer: a population-based study",
        "Association of warfarin use with lower overall cancer incidence among patients older than 50 years",
        "Use of warfarin or direct oral anticoagulants and risk of prostate cancer in PCBaSe: a nationwide case-control study",
        "The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable",
        "Cancer risk in long-term users of vitamin K antagonists: a population-based case-control study",
        "Use of oral anticoagulants and risk of prostate cancer: a population-based case-control study in Montreal,Canada",
        "Use of vitamin K antagonists and risk of prostate cancer: meta-analysis and nationwide case-control study",
        "I. Warfarin optimal duration Italian trial, incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation",
        "Does warfarin therapy influence the risk of bladder cancer?",
        "More on: vitamin K antagonists and cancer",
        "Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer",
        "Vitamin K antagonists and cancer: rebuttal",
        "Coagulation and metastasis: what does the experimental literature tell us?",
        "Contribution of platelets to tumour metastasis",
        "Anticoagulant drugs increase natural killer cell activity in lung cancer",
        "Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice",
        "The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding",
        "Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial",
        "Therapeutic targeting of the Gas6/Axl signaling pathway in cancer",
        "AXL is a key factor for cell plasticity and promotes metastasis in pancreatic cancer",
        "Warfarin blocks Gas6-mediated axl activation required for pancreatic cancer epithelial plasticity and metastasis",
        "The E3 ligase cbl-b and TAM receptors regulate cancer metastasis via natural killer cells"
    ],
    "affiliation": [
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}